Spectranetics Corporation SPNC
-
Pluristem Therapeutics' New Indication May Boost Company Valuation
By Ray Dirks : Recently , Pluristem Therapeutics' ( PSTI ) revealed preclinical data showing that its platform technology, PLX cells, is effective in a type of heart disease that has no current cures. The condition is known as diabetic diastolic dysfunction, a subset of diastolic heart disease that
-
Investors Waking Up To Pluristem's Developments
By Ray Dirks : Pluristem Therapeutics, Inc. ( PSTI ) is a sleeper among the new generation of cell therapy Companies. In the past, administering cells into the human body to address a variety of conditions has traditionally been through veins. PSTI has found a new way, one that will revolutionize
-
Spectranetics ( SPNC ): Q1 EPS of $0.00 in-line. Revenue of $33.3M (+9.5% Y/Y) beats by $1M. (PR)
Spectranetics ( SPNC ): Q1 EPS of $0.00 in-line. Revenue of $33.3M (+9.5% Y/Y) beats by $1M . ( PR ) Post your comment!
-
Spectranetics Still Searching For Traction In Peripheral
… interesting to see that there are still a few sell-side analysts willing to stick their heads out and support Spectranetics ( SPNC ). More than 25 years into its life as a medical device company, Spectranetics has yet to really carve out much more than niche …
-
Spectranetics ( SPNC ): Q4 EPS of $0.04 beats by $0.02. Revenue of $32.5M (+10.9% Y/Y) beats by $0.5M. (PR)
Spectranetics ( SPNC ): Q4 EPS of $0.04 beats by $0.02 . Revenue of $32.5M (+10.9% Y/Y) beats by $0.5M . ( PR ) Post your comment!
-
Dropping Coverage of Spectranetics Corporation
We are no longer providing equity research on Spectranetics Corporation SPNC . We provide broad coverage of more than 1,700 companies across more than 140 industries, and adjust our coverage as necessary based on client demand and investor interest.
-
Top Picks by Biotech and Medical Device Focused Hedge Fund DAFNA Capital Management
Ganaxi Small Cap Movers submits: Hedge Fund DAFNA Capital Management, LLC, based in Los Angeles, invests in publicly traded biotechnology and medical device companies. The firm was founded in January, 1999, and it uses fundamental and event-driven analysis to employ long and short investment ...
-
Dropping Coverage of Spectranetics
We are no longer providing equity research on Spectranetics SPNC . We provide broad coverage of more than 1,700 companies across a number of industry groups and adjust our coverage as necessary based on client demand and investor interest.
-
Mixed 3Q for Spectranetics
Spectranetics SPNC announced slightly underwhelming third-quarter results and reduced revenue guidance for certain products due to economic and …
-
Spectranetics CEO Geisenheimer to Retire
Spectranetics SPNC announced Thursday that chairman, president, and CEO Emile Geisenheimer would retire from those positions effective Nov. 1 …